NCT04906993: Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
- State
- Under way
- Phase
- Phase 3
- People
- 443 taking part
- Started
- 23 Jul 2021
- Primary completion
- 10 Jun 2025
- Arms
- camrelizumab combined with famitinib malate
- Results
- None posted
- 28 May 2021: Trial registered
- 23 Jul 2021: Trial started